- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01746264
Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Subjects had a brief screening visit with one of the study team members. Past medical history, current medications and a brief dietary history was taken. The dietary history was taken to assess calcium intake in a day and was obtained via the validated Short Calcium questionnaire. Blood pressure, heart rate as well as height,weight, waist and hip circumference measurement was obtained by study staff. In addition, a brief physical examination to determine Tanner stage was also completed. This involved examination of both breasts and genitalia for adolescent female and only genitalia in males. A physical activity questionnaire (IPAQ) was also administered by the study staff at this visit. A blood draw of 5 ml to measure plasma 25(OH) D, calcium, phosphorus was obtained as part of the screening visit. For girls who had started menstruating, a urine pregnancy test was also obtained.
After the screening visit eligible subjects had baseline biochemical tests and an endothelial function assessment. Study participants received a pill container with six total pills of vitamin cholecalciferol (D3) (1 pill = 50,000 IU), with directions to take two pills once a month (100,000 IU) at the same time for a period of 3 months. Compliance was assessed at the 3 month visit by counting the number of pills remaining in the container.
At 1 month, the subjects had tests for serum calcium and 25 hydroxy vitamin D levels. A urine test for random calcium to creatinine ratio was also obtained.
At 2 months, the serum calcium, 25 hydroxy vitamin D levels, and calcium to creatinine ratio tests were repeated.
At the end of 3 months, biochemical tests and an endothelial function assessment were repeated. Medical history, questionnaires, and the physical exam were also repeated.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 12-18 years
- BMI >95% for age and gender
- 25 (OH) D levels less than 30 ng/ml
Exclusion Criteria:
- 25 (OH) D levels >30 ng/mL
- Serum calcium >10.4 mg/dL
- Serum phosphorus > 4.7 mg/dl
- Pregnancy or nursing
- Current cancer
- Patients on vitamin D3 supplementation exceeding 400 IU/day
- Hypertension defined as Blood Pressure over the 95th percentile for age, gender and height
- Dietary calcium intake exceeding 1500 mg/day
- Hepatic or renal disorders
- Type 1 or type 2 diabetes mellitus
- Subjects receiving insulin, metformin, or oral hypoglycemic medications
- Subjects with malabsorption disorders (celiac disease, cystic fibrosis, inflammatory bowel disease)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Vitamin D3
Vitamin D3 supplementation at 100,000 IU once a month for 3 months
|
Vitamin D 3 at 100,000 IU once a month for 3 months
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Flow Mediated Dilatation (FMD)
Tidsramme: baseline, 3 months
|
Endothelial function was assessed by FMD, via a high-resolution Doppler ultrasonography examination of the right brachial artery.
FMD was calculated as the maximal percentage increase in brachial artery diameter (BAD) from baseline after the release of cuff occlusion.
|
baseline, 3 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
25-hydroxy Vitamin D (25[OH]D) Levels
Tidsramme: baseline, 3 months
|
25(OH)D was measured using liquid chromatography-tandem mass spectrometry.
Total 25(OH)D concentrations of each sample was calculated using internal standard, 25(OH)D_2 and 25(OH)D_3.
|
baseline, 3 months
|
Total Cholesterol
Tidsramme: baseline, 3 months
|
Total cholesterol levels were measured by an enzymatic colorimetric assay.
|
baseline, 3 months
|
Triglycerides
Tidsramme: baseline, 3 months
|
Total triglyceride levels were measured by an enzymatic colorimetric assay.
|
baseline, 3 months
|
Body Mass Index
Tidsramme: baseline, 3 months
|
Body Mass Index (BMI) is a health index for comparing weight to height.
BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared.
The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat.
A body mass index of under 20 is considered to be underweight, while a body mass index between 20 to 25 is considered healthy.
A body mass index in the range of 25 to 30 is regarded as overweight.
A body mass index over 30 is regarded as obese.
|
baseline, 3 months
|
International Physical Activity Questionnaire (IPAQ) Short Form Score
Tidsramme: baseline, 3 months
|
The IPAQ short form used asked 7 questions about activities in the last 7 days, covering vigorous physical activities, moderate activities, walking, and sitting, asking for days per week, hours per day or minutes per day.
The score is reported in metabolic equivalent (MET)-minutes per week.
Possible scores could range from 0 (inactive) to greater than 3000 MET-minutes/week (highly active).
The definition of high activity was vigorous intensity activity on at least 3 days achieving a minimum total activity of at least 1500 MET-minutes/week OR 7 days of any combination of walking, moderate-intensity or vigorous-intensity activities achieving a minimum total physical activity of at least 3000 MET-minutes/week.
Therefore a score of > 3000 MET-minutes/week was possible.
|
baseline, 3 months
|
Calcium Intake Per Day
Tidsramme: baseline, 3 months
|
Calcium intake was measured using the validated Short Calcium Questionnaire (SCQ).
This questionnaire is in the form of an spreadsheet, and asks the participant to enter the number of servings per week of various food items and vitamin or mineral supplements.
The spreadsheet calculates the daily calcium intake (mg/day) from the data entered.
|
baseline, 3 months
|
Serum Parathyroid Hormone (PTH)
Tidsramme: baseline, 3 months
|
A parathyroid hormone (PTH) blood test measures the level of parathyroid hormone in the blood.
This test is used to help identify hyperparathyroidism, to find the cause of abnormal calcium levels, or to check the status of chronic kidney disease.
PTH controls calcium and phosphorus levels in the blood.
PTH was measured by a two-site chemiluminescent immunometric assay.
|
baseline, 3 months
|
Fasting Glucose
Tidsramme: baseline, 3 months
|
Plasma glucose was measured by hexokinase enzymatic assay.
|
baseline, 3 months
|
Fasting Insulin
Tidsramme: baseline, 3 months
|
Serum insulin was measured using commercial electrochemiluminescence immunoassay kits.
|
baseline, 3 months
|
Homeostatic Model Assessment of Insulin Resistance Index (HOMA-IR)
Tidsramme: baseline, 3 months
|
This calculation measures insulin resistance, and requires U.S. standard units.
The healthy range is 0.5 to 1.4.
Less than 1.0 means the subject is insulin-sensitive, which is optimal.
Above 1.9 indicates early insulin resistance.
Above 2.9 indicates significant insulin resistance.
The HOMA-IR was calculated as: HOMA-IR = fasting serum glucose (mmol/L) x fasting insulin (mU/mL)/22.5.
|
baseline, 3 months
|
High Sensitivity C-reactive Protein (Hs-CRP)
Tidsramme: baseline, 3 months
|
A high-sensitivity C-reactive protein (hs-CRP) test may be used to help evaluate an individual for risk of cardiovascular disease (CVD).
C-reactive protein (CRP) is a protein that increases in the blood with inflammation.
Studies have suggested that a persistent low level of inflammation plays a major role in atherosclerosis, the narrowing of blood vessels due to build-up of cholesterol and other lipids, which is often associated with CVD.
The hs-CRP test accurately measures low levels of C-reactive protein to identify low but persistent levels of inflammation and thus helps predict a person's risk of developing CVD.
hs-CRP was measured using particle-enhanced immunonephelometry.
|
baseline, 3 months
|
Low-density Lipoprotein Cholesterol (LDL) Cholesterol Levels
Tidsramme: baseline, 3 months
|
The test for low-density lipoprotein cholesterol is used as part of a lipid profile to predict an individual's risk of developing heart disease.
A desirable level is <3.36 mmol/L; borderline high is 3.36 - 4.11 mmol/L; high is >/= 4.14 mmol/L.
LDL cholesterol was calculated as: LDL = Total cholesterol - HDL cholesterol - Triglycerides/5.
|
baseline, 3 months
|
High Density Lipoprotein (HDL) Cholesterol Levels
Tidsramme: baseline, 3 months
|
Total HDL cholesterol levels were measured by an enzymatic colorimetric assay.
The test for high-density lipoprotein cholesterol (HDL-C) is used along with other lipid tests to screen for unhealthy levels of lipids and to determine the risk of developing heart disease.
If a subject has a negative risk factor, a desirable HDL level would be >/= 1.55 mmol/L.
|
baseline, 3 months
|
Urine Calcium to Creatinine Ratio
Tidsramme: baseline, 3 months
|
Urine calcium/creatinine ratio (unit mg/g) on random urine sample was calculated by dividing calcium in mg by creatinine in g.
|
baseline, 3 months
|
Reactive Hyperemia Index (RHI)
Tidsramme: baseline, 3 months
|
The cuff of a sphygmomanometer was placed on the forearm and inflated to 50 mm Hg above the participant's systolic blood pressure for a period of 5 min.
The increase in resting brachial blood flow was calculated as the maximum flow recorded in the first 15 seconds after cuff deflation and expressed as a percentage increase from baseline reactive.
Higher values are considered normal or improved endothelial function.
|
baseline, 3 months
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 12-006349
- UL1TR000135 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Vitamin D3
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Aktiv, ikke rekrutterende
-
Medical University of South CarolinaThrasher Research FundAfsluttetD-vitamin mangel | GraviditetForenede Stater
-
Aga Khan UniversityAfsluttet
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National... og andre samarbejdspartnereAfsluttetHIV-infektionForenede Stater, Puerto Rico
-
Rutgers UniversityAfsluttet
-
Brigham and Women's HospitalNational Center for Maternal and Child Health Research, Mongolia; Zuun...AfsluttetD-vitamin mangel | GraviditetMongoliet
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, DenmarkAfsluttetMigræne ifølge International Headache Society (IHS) kriterier (ICHD-II)Danmark
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbejdspartnereAfsluttet
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceAfsluttetSystemisk lupus erythematosusForenede Stater
-
University of California, San FranciscoAfsluttetColitis ulcerosa (UC) | Crohns sygdom (CD)Forenede Stater